MDXG
MiMedx Group Inc
4.60$
-1.1%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 81.7% | 68.7% | 62.6% | 66.9% | 70.6% | 72.7% | 74.0% | 75.9% | 79.7% | 81.0% | 77.9% | 73.1% | |
| 42.9% | 34.3% | 21.9% | 30.0% | 36.4% | 39.6% | 39.4% | 40.8% | 44.5% | 48.5% | 51.8% | 48.3% | |
| 42.9% | 34.3% | 21.9% | 30.0% | 36.4% | 39.6% | 39.4% | 40.8% | 44.5% | 48.5% | 51.8% | 48.3% | |
| 25.9% | 22.5% | 25.7% | 22.9% | 22.2% | 21.2% | 23.0% | 23.8% | 24.5% | 22.1% | 14.9% | 14.7% | |
| 10.1% | 8.8% | 11.0% | 10.9% | 9.9% | 9.0% | 8.9% | 8.6% | 8.3% | 7.4% | 8.5% | 7.4% | |
| 10.3% | 8.1% | 8.8% | 8.4% | 8.0% | 7.4% | 7.2% | 6.7% | 6.1% | 5.7% | 6.3% | 6.9% | |
| 2.9% | 2.2% | 5.7% | 5.2% | 4.6% | 4.4% | 4.1% | 4.1% | 3.5% | 4.1% | 4.3% | 4.3% | |
| 99.3% | 40.3% | 29.7% | 27.0% | 25.8% | 26.8% | 25.0% | 25.6% | 25.1% | 25.1% | 21.3% | 23.1% | |
| 23.1% | 19.2% | 19.0% | 17.4% | 17.2% | 17.3% | 15.8% | 17.3% | 18.1% | 18.8% | 14.4% | 13.7% | |
| – | 0.6% | 0.5% | 0.4% | 0.4% | 0.9% | 0.4% | 0.4% | 0.4% | 0.8% | 0.5% | 0.5% | |
| 4.9% | 3.8% | 4.4% | 3.3% | 2.8% | 2.8% | 3.3% | 2.9% | 3.6% | 4.2% | 3.7% | 3.0% | |
| 25.9% | 20.1% | 8.3% | 7.9% | 7.4% | 6.8% | 6.5% | 5.9% | 5.3% | 4.8% | 5.2% | 5.6% | |
| 0.7% | 59.7% | 70.3% | 73.0% | 74.2% | 73.2% | 75.0% | 74.4% | 74.9% | 74.9% | 78.7% | 76.9% | |
| -99.0% | -55.9% | -56.1% | -46.4% | -40.5% | -34.6% | -31.2% | -25.6% | -18.1% | -12.5% | -17.3% | -24.3% | |
| 63.1% | 61.9% | 67.7% | 64.7% | 60.8% | 56.5% | 55.3% | 51.3% | 46.9% | 43.7% | 48.1% | 52.6% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.